Hims & Hers Health, Inc. (HIMS) Earnings Call Transcript
February 23, 2026
Earnings Call Speaker Segments
Good afternoon, everyone, and thanks for joining us for the Hims & Hers Health call covering the fourth quarter and the full year 2025. Earlier today, once the market had closed, we put out the shareholder letter for this quarter, and you can access a copy on our site at investors.hims.com. Joining me today are Andrew Dudum, who is our Co-founder and Chief Executive Officer, along with Yemi Okupe, our Chief Financial Officer. Before Andrew takes over, I should walk you through the legal safe harbor and cautionary declarations. A number of statements and projections regarding future results that appear in this presentation are forward-looking statements, built on things like our present expectations for the market, competitors, and regulation, and they carry risks and uncertainties that might make actual results vary materially. We are under no obligation to publicly update any forward-looking statement following this call, whether because of new information, future events, changes in assumptions, or anything else. The risks, uncertainties, and other factors that might cause actual results to differ from our forward-looking statements are laid out in our earnings release and SEC filings. For a discussion of these risk factors as they relate to forward-looking statements, please see our recent earnings release along with our most recently filed 10-K and 10-Q reports. In today's presentation, we also include certain non-GAAP financial measures. We point you to the reconciliation table to the most directly comparable GAAP financial measures contained in today's press release and shareholder letter. This information, plus a link to today's webcast, is available at investors.hims.com. Once the call ends, the webcast will remain archived on the website for 12 months. With that, I'll hand things over to Andrew.
Thanks, Bill. Good afternoon, all, and I appreciate you being here today. I'm thrilled to share with you the enormous strides we're taking at Hims & Hers. This begins, just as it always has, with our core conviction that every person ought to have access to the finest care quality that exists, tailored to each individual and their particular needs. At present, only those with the most wealth in our society can count on that standard of care. By keeping the customer at the heart of all we do, we're altering that reality. Across a growing range of specialties, our teams chase this vision daily; we've demonstrated that care access need not be constrained by privilege, that prices need not be out of reach, and that customers need not accept a one-size-fits-all solution. In our view, GLP-1s illustrate how medicines are reaching the market in new ways. The trends observed during the past 18 months, among them U.S. prices for injectable GLP-1s dropping over 80%, mirror a wider disruption taking place across the United States. Customers want improved access, more direct interaction, and pricing that matches what other regions of the world pay. That strain is driving a conversation that is long overdue: How can we leverage today's technology advances to help more individuals feel wonderful? We regard this point in time as the early phase of a fresh model that genuinely serves ordinary people. Netflix and Spotify transformed how individuals could reach not just a wider variety of content, but also the finest that the industry offers. Healthcare needs to move toward that same consumer-focused distribution approach. Such an evolution will require ingenuity and new commercial structures in which consumer platforms and pharmaceutical companies collaborate to help people become healthy. Our platform positions us at the leading edge of that transformation. Before we ever scaled our weight loss offering, we constructed a platform that exceeded $1 billion in revenue and reached profitability by scaling offerings such as sexual health and dermatology. These are specialties that keep expanding today with robust unit economics that let us finance the next growth opportunities. GLP-1s represent 1 such opportunity and have given the business a significant accelerant, yet they amount to a single treatment inside a single specialty on a wider global consumer platform that grows stronger and more varied with each investment we make. At the close of 2025, more than 2.5 million subscribers on our platform were gaining from our pursuit of this vision. As we roll out new offerings capable of serving our customers as they move through different life stages, we're boosting our capacity to create and sustain deep, longer-term relationships. Since only a small minority of subscribers use a compounded GLP-1 treatment, it's obvious to us that what we're building has an impact extending far past a single weight loss treatment. Drawing on the very same tech breakthroughs that have reshaped entirely the way we enjoy entertainment, the way we move between locations, and even the way we handle our money, we're delivering high-touch, personalized care to millions of individuals across additional specialties and additional geographic markets. Nobody is in a stronger position to build a world in which more people can obtain quality care. That's what we fundamentally believe, and we treat it with real seriousness. Over many years we've developed operational know-how throughout every one of our offerings, expanded customer awareness, and used scale to push broader accessibility toward personalized care. Consequently, we can now introduce new offerings and markets onto the platform faster and more efficiently than at any prior point. Whether you reside in a rural Midwestern community in the U.S... A large city in the U.K. or somewhere in between. To illustrate how our speed to market has shifted, in the past, we aimed at introducing a single new specialty annually, and each one typically demanded a few years of development prior to turning into a meaningful contributor. Offerings we've had longer, such as sexual health and hair loss for both men and women, needed three and at times even four years to surpass $100 million in annual revenue. Putting this next to how we operate now is genuinely extraordinary. As we've previously shared, our weight loss offering hit a $100 million revenue run rate under seven months post-launch, and that leaves out any contributions from compounded GLP-1s. Inside a span of three months in 2025, we introduced our new labs offering, along with hormone therapies with support for low testosterone, menopause, and perimenopause. In only 90 days, we built three separate new entry points into our platform, each one serving large, under-penetrated markets that the traditional healthcare system has mostly ignored. Although not every new offering will scale at the same pace as weight loss, early customer success and accelerating customer adoption after our Super Bowl commercial aired give us confidence that testosterone, menopause, and labs can each surpass $100 million in annual revenue in the near future. What's even more energizing is that since launch, we've determined that over 70% of lab customers may qualify for treatment plans available through the platform, and more than 95% of individuals using a testosterone support offering see a rise in testosterone levels within the first two months of treatment, with an average increase of over 80%. These three new entry points aren't merely new offerings, they represent the beginning of far deeper relationships and value for our customers; such early signals show our evolution toward providing access to more proactive and preventative care. Insights we gather through our platform can shape an expanding selection of care pathways and can simplify the process for customers to obtain support where they need it most. At this point, we're tackling things such as cardiovascular risk, metabolic dysfunction, and hormone levels, and we anticipate adding categories like performance, recovery, and sleep down the road. While we speed up building a broader offering across the U.S., we're simultaneously making major moves to grow beyond our borders. Entering additional international markets strikes us as the obvious next move to deliver the trusted Hims & Hers experience to a greater number of individuals and locations worldwide. Through our acquisition of Zava last year, we strengthened our footing in the U.K. and gained the ability to operate in Germany, France, Ireland, and Spain. Then came the LiVWell acquisition, which pushed us into Canada, 1 of the first markets expected to gain access to generic semaglutide. Only last week, we shared that an agreement had been signed to purchase Eucalyptus, a top-tier global health innovator. Once that deal closes, our U.K. and European footprint will grow even stronger, and we'll also introduce the Hims & Hers brands to additional markets including Australia and Japan. For years, I've known Tim Doyle, Co-founder and CEO of Eucalyptus, and it's been a pleasure to see him and his teams create an innovative healthcare experience centered on safe, highly accessible care that keeps customers at the heart of all they do. I have no doubt he's the right leader to make the Hims and Hers experience central to how customers in each of these new markets approach their daily health. The opportunity is significant.
We're confident that by investing intentionally and executing well, we'll have the right teams assembled to lead the category in every one of these markets, which puts our international operations on a path to exceed $1 billion in yearly revenue over the coming 3 years. Having a larger footprint spanning both specialties and geographies gives us essential foundations for the healthcare future we're building. That future rests on 3 core pillars. To bring them to reality, we're putting money into technology and infrastructure. To start, advances in diagnostics and devices will keep changing the way every individual grasps their complete health picture. Thanks to our newly launched lab, customers now receive more than 130 biomarkers covering major areas of long-term health. Those results show up right inside our app, where readouts powered by AI call out metrics already in good shape alongside ones requiring attention, and also teach customers about lifestyle and clinical interventions; through buying Your.Bio, we intend to make lab testing that is targeted and specific to conditions easier and more welcoming, using technology usable from the comfort of home. Combined, these fresh services and growing capabilities will let customers understand their health more deeply and assist providers in reaching better-informed choices. Down the road, we anticipate adding to this by integrating wearable tech, such as continuous glucose monitors and everyday fitness trackers, plus broader testing choices that deliver things like polygenic risk scores straight to our customers. Next, AI is set to serve as an essential layer atop that data, helping to define, refine, and carry out precision treatments, interventions, and lifestyle changes. Our expanding technology and product groups, which report to Mo Elshenawy and Dheerja Kaur, are making sure that as our offerings grow and richer insights reveal areas of need, we're crafting an experience that keeps proactive care easy to reach and always on hand. We picture customers being able to add, tweak, or swap treatments inside one intuitive platform as their health changes. Meanwhile, static, reactive communication is giving way to proactive conversational support that steers customers through their entire journey. Early rollouts of proactive messaging and weight loss have already produced a rise of over 50% in how often weight gets logged, which points to an ability to boost customer dedication and involvement as they move forward in their weight loss journey. On the back end, automation is stripping away burdensome processes and smoothing administrative interactions, freeing providers to concentrate on clinical decision making. What comes out of this is quicker responses, greater customer satisfaction, and a scalable model capable of bringing high-touch care to millions of people, all while keeping clinical excellence a priority. Finally, richer data and more proactive care call for treatment plans that are more precise and personalized for every customer. Achieving that at scale requires putting money into infrastructure able to provide access to personalized treatments and custom formulas that safely combine pharmaceuticals and supplements. Our guiding belief is that care decisions ought to reflect the customer's best interest, rather than insurance coverage rules or whatever happens to be sitting on pharmacy shelves. Building out the physical footprint needed to bring genuinely personalized care to people at scale has taken us many years. Just within the past 3 years, we've put over $300 million toward our facilities, growing our footprint past 1 million sq ft spanning pharmacy operations, lab testing capabilities, and R&D, which backs innovations such as peptide therapies. That groundwork lets us pair quality with wider access and ongoing innovation, so personalized care reaches people consistently throughout our platform. Deeper data and stronger technology — the first 2 pillars — are moving forward across the industry. In our view, that progress calls for the third pillar: a scalable approach that makes healthcare's final step both more precise and more personal. Our investments in technology and infrastructure, we believe, position us to lead in delivering a more individualized experience to tens of millions of customers, all while upholding the high standards customers now expect regarding their care quality. Here at Hims & Hers, the team rises each morning driven to overhaul a dated healthcare system that has declined to prioritize the customer. As we strive to fundamentally reinvent these systems, challenges should be expected. Industries need time to transform, yet we're steering this effort for our customers' sake. On the goal of getting more people access to the most innovative and groundbreaking treatments and services out there, we'll keep fighting, staying faithful to our mission that through the power of better health, we can make more people feel great. Chasing this mission requires commitment and resilience. That held true when we founded the company, and it holds true now. We'll keep advocating for better, more accessible care worldwide by concentrating on a steady set of priorities: delivering more offerings to our customers alongside more insights and deeper personalization capabilities, and, where it makes sense, joining forces with leaders who share our belief in a better healthcare experience. By investing with conviction across these priorities, we believe Hims & Hers will lead in the next era of healthcare, one that keeps evolving to serve the customer better; this conviction is what grounds our confidence in reaching our 2030 target of $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA. At Hims & Hers, we're honored to steer the shift toward a consumer-centric system. Changing what people expect from their healthcare feels both a privilege and a responsibility; it's the reason we began this mission, and it keeps motivating us daily. Thank you. I'll now pass it to Yemi to walk through the financials.
Thanks, Andrew. To kick things off, I'll give you a rundown of how we performed financially in the fourth quarter, and then I'll go deeper into what we're expecting for 2026. What we accomplished in 2025 speaks to the growing scale of a platform built around customers first, as we keep broadening access to highly personalized, high-touch care spanning more conditions, which lets us forge stronger and more valuable connections with our subscribers. The number of subscribers on our platform climbed past 2.5 million during 2025, reflecting our ongoing pursuit of the mission to help the world feel great through the power of better health. A foundational element of our capacity to bring in and keep subscribers is personalized solutions. When we talk about personalized solutions, we mean customized treatments and programs designed to tackle the primary needs and concerns of consumers. Among those needs are adjusting dosage so it fits each patient individually, making treatment regimens easier by using one solution to cover multiple conditions, enhancing what customers can choose from via alternative form factors, and delivering insights and tools powered by data that complement medical treatments. Back in 2023, we started ramping up investment aimed at widening our range of personalized treatments, and the results have been outstanding. Since 2023 came to a close, we have brought in close to 1 million net new subscribers on our platform. As 2025 ended, roughly 65%, which equals 1.6 million, of our subscribers were using a personalized treatment. The distinctive solutions we can offer don't just help bring new subscribers onto our platform — they also produce better retention and greater customer lifetime value. Additional insights and data from new offerings such as Labs will help us draw in prospective consumers more effectively for treatments in newer specialties, including hormonal support. We think this will boost subscriber engagement, and early indicators of success are already visible, with monthly revenue per average subscriber climbing 11% year-over-year to $83 during the fourth quarter. Ongoing subscriber growth and deeper engagement are converting into financial results. Fourth quarter revenue came in at $618 million, which works out to 28% growth year-over-year. Across fiscal year 2025, revenue reached $2.35 billion, a 59% increase year-over-year. The results we posted in 2025 further strengthen our belief that a substantial multi-year growth runway lies ahead across three main parts of the business: the Hims brand in the US, the Hers brand in the U.S., and a growing international presence. For our Hims brand, we generated year-over-year revenue growth above 30% in 2025, even with headwinds stemming from our intentional push to move away from generic, on-demand sexual solutions. Starting in 2023, we rolled out a number of combination treatments in our sexual specialty targeting health issues like low testosterone, heart health, hair loss, and vitamin deficiencies. Close to half a million subscribers on our platform — 0.5 million — are seeing benefits from these daily solutions, and those subscribers' year-over-year growth stayed above 30% all through 2025. As we move through 2026, we anticipate carrying this transition forward. We expect that retention gains from our daily sexual health offerings, together with the development of new offerings like testosterone support, will keep driving strong growth for the Hims brand. Now turning to Hers. Throughout 2025, our Hers segment kept up triple-digit growth in revenue and made up close to 40% of U.S. revenue. Much as with Hims, that growth increasingly comes from customers engaging more deeply across a wider range of women's health needs. We're seeing continued expansion in established specialties such as weight loss and dermatology, reinforced by fresh offerings in menopause support and diagnostics, which gives us chances to deepen customer relationships and lengthen how long they stay on the platform. Our ability to go deep across a wide range of specialties, so that we don't depend on any single offering, is what powers our domestic business. Stronger, more tenured offerings like men's dermatology, women's dermatology, and sexual health let us push past $1 billion in revenue, achieve Adjusted EBITDA net income profitability, and produce positive free cash flow; that in turn let us invest aggressively in our weight loss offering and bring a meaningful growth vector into our portfolio through access to oral and injectable weight loss treatments. Consumers have had success with both the oral solutions and the injectable GLP-1s offered on our platform, with a typical consumer reporting average weight loss of roughly 22 pounds and 29 pounds, respectively, during their first year of treatment. Even though GLP-1s have sped up our trajectory, most of the revenue and cash flow generation across our portfolio comes from our non-GLP-1 offerings. The higher margins from our more tenured offerings will be key to supplying the resources needed for investment to scale the next wave of specialties, including weight loss, lab testing, low testosterone, and menopausal support. Our consumer-centric approach has delivered enormous success in the U.S., where revenue climbed over 50% year-over-year to more than $2.2 billion. We believe the value our approach delivers goes beyond borders. In 2025, we brought Zava and Livewell into the Hims & Hers family. We can now serve consumers in Germany, the U.K., Ireland, Spain, France, and Canada. International revenue rose almost 400% year-over-year to $134 million. We anticipate that our international footprint will account for a more meaningful share of our revenue down the road. To reflect how important this is, we'll change our revenue disaggregation from online and wholesale to U.S. and rest of world revenue going forward; with that, I'll now move to profitability dynamics before going deeper into our balance sheet and future investment plans. Adjusted EBITDA in 2025 rose nearly 80% year-over-year to $318 million. On a full year basis, Adjusted EBITDA margins expanded nearly 2 points versus 2024 to 14%; during the second half of 2025, we invested meaningfully to raise the density of our technology talent, scale new specialties, and strengthen our policy and safety talent so we could keep expanding our operational footprint. Adjusted EBITDA came to $66 million in the fourth quarter, an Adjusted EBITDA margin of 11%. In Q4, gross margins fell roughly 2 points versus the prior quarter, landing at 72%. Gains from ongoing expansion in non-weight specialties were counterbalanced by rising revenue contributions from international markets, costs tied to rolling out new specialties, and pressure stemming from the shorter shipping cadences and the weight loss we addressed last quarter. The investments we've made previously in our brand and product suite remain a major factor behind our capacity to generate marketing leverage. During the fourth quarter and fiscal year 2025, marketing accounted for 39% of revenue, which marks a 7-point improvement year-over-year. Following years of spending on brand campaigns to build greater top-of-funnel awareness, we keep seeing acquisition gains through lower cost and non-paid channels. Beyond that, retention gains throughout our subscriber base are compounding, since we tackle more customer needs head-on with an expanding portfolio of personalized solutions and a customer experience that fuels stronger engagement. In Q4, G&A costs as a share of revenue rose 2 points year-over-year, driven by more international headcount and by additional expenses from bringing in new leadership talent. Across the full year, G&A costs as a share of revenue came in essentially flat compared with 2024. Operations and support costs showed a comparable pattern.
Tech and development expenses measured against revenue rose to 7% across both Q4 and the entire year. Putting money into engineering and AI talent has produced only slight leverage so far, yet we're confident the returns will be significant, since it lets us operate more quickly and upgrade what we offer consumers. Already we're seeing encouraging early indicators — shown by launching several specialties during the back half of 2025, plus our capacity to enhance the customer experience and achieve operational efficiencies. Full-year net income climbed markedly compared with the prior year, reaching $128 million, versus 2024 net income once you adjust for a tax benefit recorded in that earlier year tied to releasing a domestic tax valuation allowance. Although we intend to stay profitable on an annual net income basis, our focus remains fixed on generating free cash flow over the long term... That gives us room to broaden operational capabilities and speed up our strategic roadmap, including via M&A. During 2025, we produced $300 million in operating cash flow. Robust cash generation from our domestic operations, together with a strong balance sheet, let us aggressively deploy capital across all our priorities. To start, we directed more than $225 million toward our operations via discretionary CapEx, fueling added capacity and fresh capabilities throughout our domestic facilities, which today exceed 1 million sq ft in total. Next, during 2025 we signed deals committing over $330 million in purchase price consideration for acquisitions, which helped us speed entry into new international markets and kick off R&D work in peptides; we think Your.Bio Health, which just closed in 2026 at roughly $150 million, will eventually let us strengthen our diagnostic specialty down the road with a painless at-home option. Finally, well, we bought back about $90 million of common stock during 2025, including $80 million of shares repurchased in Q4 at an average price of $39. In Q4, we finished our $100 million share repurchase program, leaving $225 million outstanding under the $250 million repurchase program launched in November of 2025. Following significant investment throughout 2025, we threw off more than $57 million in free cash flow and closed the year holding $929 million in cash along with short-term and long-term investments on our balance sheet; we're confident that our capacity to draw on this financial position, combined with the discipline of our capital allocation framework, will let us quickly serve a wider set of consumers, keeping us on track to rank among the biggest consumer-centric healthcare platforms globally. When it comes to where we put our capital, the main focus will be on improving the way we bring data together with insights, methodically expanding tailored offerings, and enhancing both digital and brick-and-mortar customer assets so that the healthcare journey improves for tens of millions of people; over the course of 2026, we expect this to unfold in the areas outlined below. First off, we will continue directing funds toward the capacity and capabilities of our operating facilities. We believe that investing in these facilities will enable us to capitalize on insights derived from labs and eventually wearables, offering a broader array of personalized treatments. Beyond that, verticalization reduces our cost to serve, which ultimately allows us to deliver value back to consumers and selectively grow margins. Moving forward, a portion of our spending will go toward novel offerings and hardware that expand subscriber access to care. YourBio stands out as a strong illustration of that push — its blood collection approach relies on microneedles and is essentially free of discomfort, and bringing it fully into our operations and growing it to scale matters a great deal to us. Plenty of customers miss out on richer understanding of their own wellness because of obstacles like lengthy queues at packed clinics, anxiety about needle sticks, or simply not having enough hours in the day to make the trip to a testing site. We think that putting money into these things will eventually make it possible for people to get their blood drawn right at home, and AI can assist in steering providers toward whichever tests will do the most good for a subscriber at any given moment. Number three, we intend to continue funding technology. There are only a handful of platforms with visibility into the patient journey all the way from intent through to outcomes, and adding labs makes that distinctive capability even broader. For us, the things that set us apart are a top-tier product experience, a provider network of high quality, and personalized solutions that are supported by data. Over time, we anticipate that these investments will strengthen customer engagement and retention, and also open up gains in operational efficiency. Fourth, we anticipate continuing to grow our partner network, which will strengthen our capacity to serve as a curator of world-class healthcare services. In the years ahead, we aim to team up with additional companies that share our vision, so we can unlock greater value for our customers. When it comes to our most significant areas of investment in 2026 and beyond, international expansion may well be at the top of the list. We recently completed a deal to bring Eucalyptus into the Hims & Hers family. Once that transaction closes, Eucalyptus will round out Zava and strengthen our footprint in the UK, while also opening up a model that aligns more closely with our domestic business across Germany, Australia, and Japan. Should the deal go through, we anticipate that our combined overseas operations—Eucalyptus included—will reach the break-even point somewhere between 12 and 18 months from now. Eucalyptus applies a disciplined approach to allocating capital much like the one we use; at present their yearly revenue run rate sits at $450 million, and thanks to solid execution they achieved triple-digit growth compared with the prior year in every quarter of 2025, all while keeping profitability within reach. Although we don't anticipate this business generating sizable Adjusted EBITDA losses, neither do we foresee substantial margin expansion in our international business for a number of years. For most of our overseas markets, our plan is to prioritize growth and bring in as many customers as we can before we shift attention to improving margins — even if some of those markets end up operating at or close to breakeven when measured by Adjusted EBITDA margin. That strategy proved successful in the U.S., and we intend to apply a comparable playbook to steadily bring markets along toward margin expansion down the road. This deal stands as the biggest acquisition we've completed so far, with total consideration of up to $1.15 billion. At closing, the upfront payment is anticipated to come to roughly $240 million, while the rest of the guaranteed consideration and earn-out payments will be paid out through 2029. Just as we've done previously, we'll keep watching the landscape for chances to strengthen our balance sheet so we retain optionality, doing so in ways that give careful thought to dilution; even so, we're ready to cover most of the Eucalyptus transaction using the strength of our current balance sheet and the cash flow our domestic operations generate through 2029; with that said, I'll share some further detail on our preliminary outlook for 2026. Just a reminder that these numbers leave out the Eucalyptus deal. For Q1, our revenue guidance is $600 million to $625 million, representing 2%-7% growth compared with a year ago. On Adjusted EBITDA, we expect something in the range of $35 million to $55 million, and at the midpoint of both ranges that puts the Adjusted EBITDA margin at 7%.
Looking at the full year, we anticipate revenue somewhere between $2.7 billion and $2.9 billion, which would mark a year-over-year rise of 15% to 24%. Our expectation is that 2026 Adjusted EBITDA will land somewhere in the range of $300 million to $375 million. When you take those Adjusted EBITDA and revenue ranges together, they imply an Adjusted EBITDA margin of 12% at the midpoint of both. Several assumptions sit behind this outlook. First, we anticipate a revenue headwind of roughly $65 million during the first quarter, driven by changed shipping cadences in our weight loss business after the move to 503A fulfillment. To give some context, during the second half of 2025, that revenue headwind comes to approximately $40 million; we expect this effect to lessen as cohorts keep stacking across the year. Worth noting is that these dynamics impact only when revenue gets recognized, not customer demand or engagement. Demand for weight loss stays strong, with subscribers up more than 70% year-over-year in the fourth quarter. Throughout 2026, we expect subscriber growth in our weight loss offering to stay strong. Second, additional EBITDA pressure in the first quarter is expected to come from our investment in our 60-second Super Bowl commercial. That investment was instrumental in letting us educate consumers about our platform, and also in evolving the brand toward being known for proactive healthcare solutions. We don't expect any change to our framework calling for a payback period of under one year on marketing spend. From the first quarter onward, we expect Adjusted EBITDA margins and revenue growth to scale. Third, we expect several of the newer offerings — things like low testosterone, menopausal support, and labs — to scale incrementally throughout the year. These newer offerings will be key to keeping solid growth at Hims, and to helping the Hers portfolio keep scaling and reach its first year of $1 billion in revenue. Investment across most offerings will be stage-gated, with incremental investment released as these new offerings hit unit economic and scale milestones. We believe each of these offerings can drive meaningful future growth and will be critical to our ability to obtain our 2030 aspirations. Fourth, investment in our platform's product experience, technology, and AI capabilities should become a bigger priority in 2026. We believe we're uniquely positioned to connect deeper health insights with improved conversational support that's available whenever our customers need it. Our guidance gives us the flexibility to lean into these opportunities to create a more engaging customer experience from start to finish, driving stronger conversion and retention over time. Finally, international expansion will be a meaningful driver of incremental growth in 2026. Our initial outlook anticipates at least $200 million in revenue contributions from international markets. That includes any additional contributions from our acquisition of Eucalyptus, which should close in the second half of this year. If the deal goes through on the timeline we anticipate, we'd look for the back half of the year to bring in no less than $200 million in extra revenue. Growth expansion will be the main thing we're aiming for internationally. Meaningful Adjusted EBITDA losses aren't something we anticipate, though we do think newer markets abroad will operate close to breakeven. We came out of 2025 carrying a lot of momentum, which has kept us delivering fresh sources of value to millions of subscribers. Because of how well we've done in the U.S., we're positioned to expand deliberately and scale quickly in international markets including the U.K., Germany, Canada, Australia, Japan, and others. Robust free cash flow and Adjusted EBITDA from mature specialties in our domestic business will let us keep broadening specialties while at the same time growing subscribers in strategic markets. Over the near term, we anticipate a number of these markets outside the U.S. operating at breakeven, yet over the medium to long term they should turn into substantial growth and profitability vectors as we optimize and capture economies of scale, much like what we accomplished in the U.S. Ongoing U.S. growth, paired with how large the international opportunity ahead of us is, strengthens our confidence that we can hit or beat the 2030 ambitions we laid out last year. No less than $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA. None of this would be achievable without the considerable work of Hims & Hers team members across the globe. I want to express my thanks to them, to our subscribers, and to our shareholders for backing our mission of helping the world feel great through the power of better health; with that, I'll hand the call back to Bill now so we can start Q&A with two questions from our retail community.
Appreciate that, Yemi, and I want to thank each person who submitted questions across the weekend. Starting with Jay, who raised a point about how our international presence keeps expanding; since the Eucalyptus deal speeds up our overseas push into Australia and Japan while also strengthening what we already have in Western Europe, would you talk more about the company's vision for the long haul and the main priorities for worldwide growth across the coming 3 to 5 years? What's your approach for folding Eucalyptus's operations and brands together so they generate synergies?
Yes, thank you, Bill, and I appreciate the question, Jay. Look, from the start, our belief has always been that this vision of putting consumers at the center of health was something meant for the entire world. When you consider what excellent healthcare means, it's what matters to us on the most personal level. It's what matters for our families. And regardless of location — the U.S., the U.K., Germany — whenever you speak with real people, the frustration they feel toward how things currently work is the same. So our global ambitions are genuinely enormous. What sits at the heart of this is going after the 10 most essential markets and winning them decisively within the coming 12 to 24 months. Through the Zava and Livewell acquisitions, plus bringing Eucalyptus into the fold, those crucial components are now in place, I believe. I've been acquainted with Tim Doyle for close to four to five years now. He founded Eucalyptus and serves as its CEO, and watching that team deliver has been something I've truly enjoyed. They are outstanding leaders who share a deep dedication to the consumer, so when I consider these two combined, we hold ambitious goals for the Hims and Hers brand to become unified across every one of these significant markets inside the next year and 2, along with a North Star of more than $1 billion in additional international revenue over the coming few years as well.
Appreciate that, Andrew. We now have a question in from the Hims House retail community. When it comes to growth figures over the coming few years, what effect do you anticipate from regulatory and legal scrutiny? In what ways will you lower the risk posed by a possible prohibition on compounding GLP-1s? Which categories sit in the strongest position to shift the business away from GLP-1s?
Yeah, that’s a really good question. I think maybe we should take a step back for a moment. Nearly 10 years ago, when I started this company, the goal wasn’t to sell treatments through a website. It was to change the way customers get access to excellent care, and I believe that opportunity is still just as strong today as it was back then, almost a decade ago. When we began, for those who’ve been tracking us, we were often referred to as the Viagra company, right? Our business was only in ED. For many years, that was what people talked about, that was the worry—the reliance on Viagra, on that category. Then, as we moved forward and started the Hers business, and it was getting off the ground, concerns emerged: “Hey, maybe this is just a Hims business. Maybe Hers can’t replicate itself or scale as well.” Now that business is, you know, on track this year, hopefully, to hit $1 billion-plus in revenue. I think the truth is, Hims & Hers has always been and still is about more than one treatment. If you look at the business today, it’s key to keep in mind that most of our revenue and profitability comes from offerings outside of weight loss. In fact, the number of patients actually using compounded GLP-1s is, you know, a pretty small minority of the total subscriber base. So when it comes to, you know, shifting the business to, you know, handle what’s happening in the ecosystem, I don’t think that’s how we see it internally. I think we intend to keep operating the way we always have: steadily growing what we offer to patients, widening the assortment on the platform and the care we provide, strengthening our relationship with them, deepening our understanding of them, growing new categories such as labs, menopause, and low T, focusing on innovation and R&D for future areas like peptides, which we’re working on right now, and in the end, adding more value to customers’ lives in an expanding set of markets. I think with our existing diverse business lines, the speed of the new expanding categories I, you know, mentioned in the prerecorded remarks, and now this, you know, accelerating international business, there’s really never been a moment in our company’s life when we’ve had such durability and a growth engine to achieve, you know, the much broader vision for the business.
Appreciate that, Andrew. So now I'll hand things back over to the operator, and then we can kick off analyst Q&A in the usual manner.
Thanks. I appreciate you taking my questions. To start, I'd like to ask about the U.S. weight loss business, and perhaps build a bit on what was asked previously. With all the heightened attention on compounded GLP-1s, how should investors view the staying power and potential growth trajectory of that business across the coming years? Then second, on a wider note, how is your marketing mix shifting as you move into broader, less stigmatized health categories here in the U.S.? And are you noticing structural gains in CAC and lifetime value as your brand continues to mature?
Yes, excellent question, Maria. I'll take the first part, and let Yemi address the second. When we examine the domestic weight loss business, the range of assortment keeps growing, which I believe matters a great deal. We prioritize what matters to patients. Looking at the next generation therapies the big drug companies are launching, and considering the biotech pipeline in phase II and phase III, we firmly believe that within the next 2 to 3 years, there will be 12 or perhaps 24 additional treatments that will significantly improve people's lives. For us as a platform and for our patients, we strongly believe assortment is critical. I think we'll keep adapting the model as needed to guarantee we offer the breadth of assortment patients require and desire. As Yemi mentioned in our remarks, even before we had the compounded GLP-1 business line, our weight loss offerings were the fastest category to ever launch. Simply with our combinations of therapies targeting conditions related to metabolic and insulin-resistant dynamics, that business reached a $100 million run rate in only 7 months; we believe there's a truly durable weight business, even under a draconian scenario where compounding GLP-1s aren't available. I think that's even more true when you consider the expanding assortment of therapies over the next year and two, which will be very important to patients. We'll need to keep evolving that offering and category, just as we do in other categories, to ensure we have great treatments that patients are really seeking.
Regarding the second portion of what you asked, Maria — specifically how we expect acquisition patterns to develop — you can observe part of that in the marketing leverage we managed to capture, which was fairly considerable during 2025. What we're essentially noticing is that we gain an advantage from the wide range of treatments available through the platform, along with the spending we've undertaken over time focused on really showing consumers just how capable the platform is. Given all that, we believe it hands us an edge over competitors when it comes to acquiring customers... Beyond that, especially as we move into newer specialties such as labs, we'll be positioned to deliver richer insights to consumers and to shift toward an environment centered more on proactive care. In our estimation, that holds enormous promise for pushing acquisition efficiency even higher. On the LTV side, what we're seeing is that when we can assist our providers on the platform in matching consumers with personalized treatments that are genuinely distinctive and suited to what they need, that in turn produces better retention throughout the platform. That could mean, as we mentioned during the prepared remarks, tackling several conditions via simpler mechanisms, or assisting users in reconciling effectiveness against adverse effects, or supplying different form factors. Each of those elements, plus the capacity to draw on an expanding set of insights that help providers match consumers with such treatments, is something we see producing better retention — which in the end generates greater lifetime value for the consumer.
That's really useful. Many thanks.
Excellent. Thanks. Good afternoon. I'd like to dig a bit deeper into certain investments you're making; from what I hear, across AI, labs, and wearables, you're setting up the groundwork for a flywheel later on. I'd really like to learn more about exactly how far you intend to push into the wearables space, what timeframe we ought to keep in mind for the investments backing some of these efforts, and how we should view labs, the path to expanding labs across the coming year or thereabouts. Thank you.
Yes. Thanks, Justin. Yes, I'd say those 3 areas are a genuine priority for the company. And stepping back, you know, there has simply never been a simpler method to gather more sophisticated data from patients via these tools, be it wearable devices, be it polygenic risk scores, which you can obtain through a swab inside your mouth, be it cancer testing or full gene sequencing. I mean, it's truly remarkable. So as that speeds up, and our investments in YourBio speed up, and we can secure at-home testing at lower, lower, lower prices, you know, we'll be verticalizing that infrastructure so that you, as a member of Hims & Hers, can be obtaining access to this sort of data collection quite regularly. I believe that intelligence layer, which then helps grasp how we stay ahead of what you're battling with or what you might battle with later on, is going to become a more and more vital piece of the business. So, this is where I think, you know, the platform truly shifts from, you know, concentrating on one treatment to proactive preventative care. I genuinely believe that kind of care is, by itself, a fresh category for Hims & Hers; it's nearly like, you know, a longevity category, if you will. I think once people begin to grasp that a platform such as Hims & Hers provides you with access to what the 1% have and enables you to take the required steps to stay ahead of it, it's hugely empowering, correct? We intend to go deep across all 3 of those areas. On the device side, either via our own or via partnership; we've clearly already bought our own blood testing device, through our own AI efforts and teams, which we've already begun to launch alongside the labs efforts. It's beginning to deliver results, correct? When you, when you look at the prepared remarks, we shared that, you know, 70% of people who do a lab test on the Hims & Hers platform identify an area of risk that is treatable on the Hims & Hers platform, correct? In most cases, this is information patients are hearing for the first time — that they are pre-diabetic, that they face a risk of cardiovascular disease, and so on. In that situation, there's a huge flywheel effect from making the starting point for gathering data and finding out about your own health incredibly low and incredibly simple to begin, and then eventually creating value across the long term with those patients as we broaden our care and are able to take a more comprehensive view of their health.
Yes, and what I'd tack on there, Justin, is that, as with our previous approach, we're going to stay deliberate and keep using stage gates for the spending. A lot of where the money is going fits within those 4 pillars we've consistently referenced — the brand, the tech and data outlays that strengthen the personalization and distinctive offerings we can provide, plus the power of our provider network. So what you're seeing right now, I think, is a really substantial balance sheet along with robust free cash flow, which lets us pursue the shift Andrew brought up toward a platform more centered on using data to serve consumers proactively. In the end, we believe these outlays, once they begin converging in 2026 and even in later years, can swiftly generate positive ROI and eventually cover their own costs, turning self-funding. That could come through greater lifetime values, which we covered in the prior question, or simply through proactive care, opening up fresh insights for consumers that boost acquisition efficiency via cheaper channels. All of those are levers we'll track and keep pushing on, and we ultimately think they can make these outlays essentially cover themselves quite fast.
Great. Thank you both.
Yes, thank you. Regarding certain older core products, could you discuss the areas you anticipate will fuel expansion in 2026? And regarding weight loss, are you incorporating a specific range into your outlook for this year?
Yeah, I appreciate that question, Craig. Perhaps I'll kick things off. I believe that more and more, the very idea of — well, I'd just like to flag that the very idea of core versus, say, non-core is growing less and less pertinent. The way we're steering the company, since boundaries between specialties keep merging further and further, is truly centered on the split between international and domestic. Below that level, what you observe is that you have operations of differing maturity, differing maturity. You know, we perceive, you know, considerable opportunity across both the Hims and Hers specialties, you know, for ongoing expansion. It was exciting, I think, to watch the Hims brand expand 30% year over year in 2025. We hold the belief that we're set up for ongoing expansion, be it through newer specialties such as testosterone that are appearing quickly, or even once we begin to realize the gains from improved retention on the daily health products in both sexual health and a wider selection in other areas such as hair. Every one of these disciplines possesses the capacity, you know, with the Hims specialty, to keep fueling expansion. And then turning to Hers, what we're observing is, you know, quite much the, you know, identical situation. In the past, you know, categories we introduced more recently have required, you know, 12 to 18 months to reach scale. I believe that when we consider items such as labs, menopausal support, along with certain longer-established categories such as Hers care, we keep witnessing strong expansion throughout many of those, and I think we will keep on, on putting money into those. As we complete the shift Andrew brought up, you know, earlier, and concerning this proprietary marks and then the, the matter, we can proactively serve consumers, you know, consumers. I think that will be a fairly significant unlock, which will deliver the capacity to, you know, allow us to keep seeing our longer-established specialties expand.
Understood. And to build on that, if I consider the 2030 objective and the route toward a 20% margin, you've mentioned on a few occasions that overseas operations are roughly at break even, and that investments are being made there. Is there anything involving the U.S. business or cost efficiencies that could help offset part of that pressure coming from international operations, purely from a margin standpoint?
Yes. I wouldn't say that the pressure from international is something that will be, you know, permanent in nature. What I believe we'll do — and this will likely play out more market by market — is examine whatever opportunity, you know, sits before us. Across the majority of international markets, I'd say the focus is going to lean toward growth. I'm not certain that our international footprint will stay static, especially as we, you know, keep leveraging the assets we currently have along with the Eucalyptus team to enter new markets. Markets that are newer will generally have a tougher margin picture. When we, you know, consider markets that mature over the coming 2 to 3 years, ones where a solid presence already exists, there's a chance, you know, to begin seeing margin improvement once you're 2 to 3 years in. If you, you know, examine how things unfolded in the U.S., and how we shifted from, you know, domestic operations losing money to becoming profitable, the margin climb that came with achieving economies of scale, you know, between 2022 and 2023, happened quite quickly. Our expectation, I'd say, is that market by market, something comparable will occur internationally; and regarding domestic operations, we're putting money in, you know, quite aggressively across a, a set of specialties with less tenure. Once those specialties reach their, you know, milestones and stage gates, we'll keep investing. What you'll also notice is that specialty by specialty, the gap between the more tenured specialties and the newer ones — their margin profiles begin to come together. So I'd say through that, plus domestic operations and the market-by-market dynamic internationally, you know, in the back half of this decade, things become increasingly margin accretive. That's how we see, as, as the route to reach our, reach our targets of $6 billion in revenue and $1.3 billion of, of Adjusted EBITDA.
Understood. Thanks very much.
Thanks. Andrew, I'm curious to hear how you see the makeup of the overseas business shaping up over the next 12 months, spanning both Zava and Eucalyptus, when it comes to the specialties or personalization. And then, I recall you mentioned that line about turning into a top provider of branded GLP-1 medications. Is that just a matter of what's already flowing through Juniper right now? What's your thinking on keeping ties strong with the brand manufacturers?
Sure, Eric, that's a fantastic question. So, as the international side matures, my guess is it will eventually end up looking a lot like the U.S., correct? There's substantial category growth happening abroad, and every one of these companies that we're bringing into the fold has distinct areas of emphasis across various markets, right? In Australia, the Pilot brand is heavily centered on men, while Juniper is centered on women and weight. In the end, we believe it will likely come together to deliver genuinely strong diversity once it reaches scale. Abroad, I'd say the ties with our global teams and the branded pharma partners are pretty robust, since there's real steadiness there — they've built excellent rapport and have managed to serve as a major consumer distributor for those companies. My expectation is that this continues and holds steady; we don't anticipate altering that approach. In my view, that's the approach that wins internationally, and I'd anticipate it stays that way.
Appreciate it. To build on that, when you mentioned most of the business isn't weight loss, did that refer to both revenue and free cash flow, or was it cash flow?
Right, right. What I was getting at is that most of the money we bring in right now actually originates beyond the GLP-1 segment. You can put that down to our longer-established specialties, which deliver a healthier margin thanks to scale efficiencies. On top of that, with categories that have matured, Adjusted EBITDA — or the margin picture — usually comes out higher.
Thank you.
Thank you. I'd like to pose a couple of questions regarding the fertility opportunity in the US that you're observing, and also labs so far. You've discussed both of these previously. Could you provide us with a fuller update on the data points you're seeing and your thinking around those opportunities? Thank you.
Yeah. Thanks, Mark. Nothing has been launched by us yet in the fertility space. Over the past couple of months, we have launched menopause, perimenopause, and low T, along with labs; those tend to occur alongside each other. Thus far, I'd say simply, you know, close to 10 years of trying out go-to-market strategies, I'd say the early data has us incredibly encouraged. I think our belief is that all three of those have near-term chances to scale to a $100 million run rate, much like numerous other winning categories of ours. We also observe that the actual engagement with the experience from a consumer standpoint is engagement of a very high value. On the hormonal side, massive increases in testosterone levels are being seen by men, who are feeling better. Retention indications are showing it's in line with some of our best-in-class categories. On the lab side, also, it's just giving people data that frankly used to cost somewhere between, you know, $5,000 or $10,000; it's an immense amount of knowledge, and then from there, 70% of those people are identifying an area of concern and an area of clinical risk that the platform can actually help treat. I, I think in hormones and labs both, we're incredibly encouraged. Dedicated efforts are in place on both of those, and I'm, I'm fully convinced that they will be, you know, big parts of the business going forward and, and for the coming years.
Thanks a lot.
Hi there, good afternoon, everyone. Yami, perhaps a fast one from me. When I consider the guidance range — and it's a rather broad span — where it might decline or climb during the year, I'm just wondering which swing factors we ought to keep in mind that would create that variability. Appreciate it.
Sure, that's a terrific question. A great deal of it comes down to, as you know, what we've done through the years. We use stage gates for a lot of our investments, so when scale milestones get reached, or once unit economic profiles are attained, we typically lean in a bit further. Looking toward the close of 2025, we brought out 3, 3 specialties that in our view could be rather transformative for the platform; so our guide, I'd say, delivers the capacity and the room to lean into scaling those specialties further should we observe them showing encouraging signals on the unit economic side. We talked somewhat about the way we're putting money into Tacimen, and a portion of the ROI we anticipate seeing from that. On top of that, baked into our guidance is the room to keep moving forward with a lot of those investments when they demonstrate signs of success; the last investment area, as we discussed, is really the international business — both regarding the integration of the assets with certain companies we've already closed on, for example Livewell, along with Zava; and also, with Eucalyptus possibly arriving in the second half, we want to give ourselves a range broad enough to invest throughout all those areas. Should we spot meaningful growth opportunities in technology, meaningful growth opportunities in new specialties, or meaningful growth opportunities in international markets, we certainly want to adopt the growth orientation and pursue them, since we believe — as we've shown before and through recognizing past patterns — that our teams are quite skilled at expanding margins as scale increases.
Understood. That's great, thanks.
Yes, I appreciate you fielding my question. Hi there, I was hoping to build on the point about US revenue for 4Q climbing 17%. I found myself wondering, if one were to break out the compounded GLP-1 revenue, does that compounded GLP-1 act as a drag or a boost on that figure? The cause of my asking, correct, is that, you know, Andrew, you were mentioning something along the lines of it turning into a very minor portion of the subscriber base, and yet, Yami, you described it as a $65 million drag in 1Q. I'm attempting to square all of those data points and, and how we ought to consider, you know, the contribution right now, especially as it relates to the, the fiscal 2026 guidance. Thanks.
Glenn, perhaps, perhaps, perhaps that's where I should begin. Well, you know, what you're actually seeing, you know, sort of in that move away from Q4, and then I believe you'll truly notice it in Q1, is simply that we've got a change toward recognizing less revenue per order. That isn't merely a change among new customers. I believe it's a change throughout the whole business that has gradually occurred across the past, you know, 3, you know, let's say, 2 to 3 quarters. The ticket size for the GLP-1 business, you know, is, is somewhat bigger, you know, than what we have in our core business, so the revenue impact as well as the EBITDA impact, you know, that we observe there, you know, is, is, is reasonably significant. Having said that, I believe while GLP-1 has been a significant growth driver for the platform, across the past year, as we sort of noted in the prepared remarks, the bulk of the revenue comes from the non-GLP-1 business. As we keep diversifying, we anticipate that pattern will persist. Andrew, I'm not certain whether there's anything you wished to add more broadly.
Nope, I think that's right. Thanks, Yami.
All right.
Hey there, I appreciate you fielding my questions. Andrew, clearly there's been quite a bit of news since the pill came out and then got taken off the market. Could you update us on where matters currently sit from a regulatory standpoint — have there been any discussions with the FDA or DOJ, and how much concern would you say exists surrounding this? My other question concerns something you said earlier. I believe it came in response to the first question. You mentioned that the pipeline is quite robust, with at least 12 or 24 treatments arriving over the next 2 years. When you consider how to back that wider assortment, do you expect to accomplish it through branded partnerships as those products reach the market, or will you keep following what the business has historically done and concentrate on personalized offerings instead? Thanks.
Yeah, Brian, that's a great question. On the pill side — and the same goes for the others — there's likely not a whole lot we're able to say. I think our view is that the pill carried forward the strategy of widening more personalized choices for patients on the platform, and we invested many months into it. I think we ultimately withdrew it so we could prioritize, frankly, simply engagement along with our relationships with ecosystem stakeholders. We spoke with a fair number of them at launch, came to understand their dynamics, and opted to put them first in those discussions, which is why we made the decision to pull it. As for the FDA and DOJ, I don't believe we're able to reveal very much regarding anything in progress, though we remain open to their conversations and, as we've said previously with the FDA, we feel very strongly that they serve an important, important function in keeping consumers safe, so we're glad to cooperate with them in identifying the areas of concern. Turning to the pipeline, if you look specifically at the weight loss category, I think an accelerating number of treatments will be reaching the market on the branded side of the business. This is next gen biotech, sitting in phase II and phase III. These are some of the larger players. I do believe consumer sentiment and consumer demand will keep shifting. You can observe that over the last few years since these drugs first reached the market, with the launch of Zepbound vials. You can see traffic dynamics shifting rather materially when you look under the hood. I think that's simply going to be how this category evolves, with more and more options becoming available. They'll sit at various price points. They'll carry differing side effect profiles. Different providers will be the ones associated with them. As we've mentioned regarding every one of our segments, breadth has proven to be genuinely important for us. I believe we will keep developing our platform, our partnerships, and the way we do things, to ensure that what sits on the platform matches what people are after. We aren't locked into one particular approach, in my view. To this point, we've put the consumer first, based on what we believe serves them best and what they seek and desire. When that shifts, we'll shift alongside them.
That wraps up the Q&A portion. Everyone, we're now finishing the Hims & Hers earnings call for the fourth quarter of 2025. We appreciate everyone for participating. You're free to hang up at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Hims & Hers Health, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Hims & Hers Health, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.